Evidence map›Paper›PMID 33768159›Full record

ArticleExpert review of precision medicine and drug development2021

Proteome-based pathology: the next frontier in precision medicine.

Michael H Roehrl, Victor B Roehrl, Julia Y Wang

Abstract read
In one paragraph

Article in Expert review of precision medicine and drug development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael H RoehrlDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Victor B RoehrlCurandis, New York, NY.
Julia Y WangCurandis, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Proteomic Characterization of Genomically Complex SarcomasR21CA251992 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2020 to 2020
$487k
Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic ProgressionR21CA263262 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2021 to 2022
$450k
Targeting Multiple Colorectal Cancer-Specific EnhancersR21CA231109 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PTASHNE, MARK S · 2019 to 2020
$430k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA231109NCI NIH HHS R21 CA251992NCI NIH HHS R21 CA263262
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

autoimmunitycancerclinical trialdiagnosticsdrug developmentmass spectrometrypathologyprecision medicineproteomics

Identifiers

PMID33768159
PMCPMC7986930

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.